| 000 | 01589 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250517151933.0 | ||
| 264 | 0 | _c20180612 | |
| 008 | 201806s 0 0 eng d | ||
| 022 | _a1463-1326 | ||
| 024 | 7 |
_a10.1111/dom.12986 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHanefeld, Markolf | |
| 245 | 0 | 0 |
_aEfficacy and safety of lixisenatide in patients with type 2 diabetes and renal impairment. _h[electronic resource] |
| 260 |
_bDiabetes, obesity & metabolism _c11 2017 |
||
| 300 |
_a1594-1601 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aClinical Trials as Topic _xstatistics & numerical data |
| 650 | 0 | 4 |
_aDiabetes Mellitus, Type 2 _xcomplications |
| 650 | 0 | 4 |
_aDiabetic Nephropathies _xdrug therapy |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aGlomerular Filtration Rate |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPeptides _xtherapeutic use |
| 650 | 0 | 4 |
_aRenal Insufficiency _xcomplications |
| 650 | 0 | 4 | _aSeverity of Illness Index |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aArteaga, Juan M | |
| 700 | 1 | _aLeiter, Lawrence A | |
| 700 | 1 | _aMarchesini, Giulio | |
| 700 | 1 | _aNikonova, Elena | |
| 700 | 1 | _aShestakova, Marina | |
| 700 | 1 | _aStager, William | |
| 700 | 1 | _aGómez-Huelgas, Ricardo | |
| 773 | 0 |
_tDiabetes, obesity & metabolism _gvol. 19 _gno. 11 _gp. 1594-1601 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/dom.12986 _zAvailable from publisher's website |
| 999 |
_c27119636 _d27119636 |
||